Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-Dose Study of SGN-33 (Anti-huCD33 mAb; HuM195; Lintuzumab) in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT00283114 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00283114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00283114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-Dose Study of SGN-33 (Anti-huCD33 mAb; HuM195; Lintuzumab) in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2005
Completion date
January 31, 2010
Enrollment
82 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, myeloproliferative disorders